Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $39.72 and last traded at $39.8650, with a volume of 996783 shares trading hands. The stock had previously closed at $38.98.
More Teva Pharmaceutical Industries News
Here are the key news stories impacting Teva Pharmaceutical Industries this week:
- Positive Sentiment: Teva reported new Phase 3 SOLARIS data for investigational once-monthly olanzapine long-acting injectable (LAI) TEV-749 in adults with schizophrenia. The program could strengthen Teva’s central-nervous-system pipeline and provide a future growth opportunity if approved. Teva Pharmaceutical Industries Why Is It Back In The Spotlight
- Positive Sentiment: At Psych Congress 2026, Teva presented additional analyses from the SOLARIS trial and new data on UZEDY®, its long-acting schizophrenia treatment using Medincell’s drug-delivery technology. The updates support investor interest in Teva’s long-acting injectable franchise, although they do not yet represent regulatory approval. Medincell Partner Teva Presented New Data
- Neutral Sentiment: Teva’s U.S. All Stars Conference presentation transcript may provide additional commentary on its pipeline and business outlook, but the available report does not identify a specific new catalyst or material change in guidance. Teva Presents at U.S. All Stars Conference Transcript
- Negative Sentiment: Director Roberto Mignone sold 367,600 Teva shares for approximately $14.36 million. The large transaction, disclosed after Teva’s recent gains, may raise concerns about insider confidence and add near-term selling pressure. SEC Filing for Roberto Mignone Share Sale
- Negative Sentiment: Insider Brian Savage separately sold 7,342 shares valued at about $285,000, reducing his ownership by 46.35%. While smaller than the director’s sale, the additional insider transaction reinforces the negative sentiment around near-term trading. SEC Filing for Brian Savage Share Sale
Analyst Ratings Changes
A number of research analysts have recently commented on TEVA shares. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research report on Tuesday, July 28th. Barclays upped their price target on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Wall Street Zen cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings downgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. Finally, Leerink Partners assumed coverage on shares of Teva Pharmaceutical Industries in a report on Wednesday, September 9th. They issued an “outperform” rating and a $45.00 price target for the company. Ten research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus price target of $43.10.
Teva Pharmaceutical Industries Price Performance
The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. The company has a market capitalization of $46.10 billion, a PE ratio of 65.93, a price-to-earnings-growth ratio of 4.99 and a beta of 0.87. The firm’s 50 day simple moving average is $35.73 and its 200 day simple moving average is $33.65.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last released its earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.14 billion during the quarter. As a group, research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.94 EPS for the current fiscal year.
Insider Activity
In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 367,600 shares of the firm’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Brian Savage sold 7,342 shares of the stock in a transaction that occurred on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider owned 8,500 shares in the company, valued at approximately $330,225. The trade was a 46.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 374,959 shares of company stock valued at $14,644,285. 0.54% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in TEVA. Norges Bank purchased a new position in Teva Pharmaceutical Industries during the fourth quarter valued at $1,098,060,000. WCM Investment Management LLC lifted its stake in Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after buying an additional 26,813,522 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd boosted its holdings in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock worth $1,171,378,000 after buying an additional 5,917,423 shares during the last quarter. Castle Hook Partners LP acquired a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $82,013,000. Finally, Capital World Investors purchased a new stake in Teva Pharmaceutical Industries during the 4th quarter worth approximately $73,687,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. The company develops, manufactures and markets generic medicines, innovative specialty medicines, biosimilars, over-the-counter products and active pharmaceutical ingredients. Its portfolio serves a broad range of therapeutic areas, including central nervous system disorders, respiratory conditions, migraine, oncology and movement disorders.
Teva’s specialty medicines include treatments for conditions such as multiple sclerosis, migraine and tardive dyskinesia, while its generic medicines business supplies products across numerous therapeutic categories and dosage forms.
Featured Articles
- Five stocks we like better than Teva Pharmaceutical Industries
- AutoZone Shifts Gears, On Track to Reverse Course and Price Recovery
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
